ArticlePituitary2026
External validation of the PANOMEN-3 classification for predicting 1-year surgical remission in pituitary adenoma.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe PANOMEN-3 classification was developed as a multidimensional framework to improve prognostic stratification in pituitary adenomas. While prior validation studies have primarily focused on long-term outcomes, its value in predicting early postoperative remission remains less well defined. We aimed to externally validate PANOMEN-3 for predicting 1-year remission in a single-center surgical cohort.
methodsThis retrospective study included 77 consecutive patients who underwent transsphenoidal surgery for pituitary adenoma between June 2023 and January 2025. Tumors were classified according to the WHO 2022 criteria and graded using the PANOMEN-3 system. The primary endpoint was remission at 1 year, defined biochemically for functioning tumors and radiologically for non-functioning tumors. Logistic regression analysis was performed to evaluate the association between PANOMEN grade and remission. Receiver operating characteristic (ROC) analysis was used to assess discriminative performance.
resultsAt 1-year follow-up, remission was achieved in 52 of 77 patients (67.5%). Remission rates declined with increasing PANOMEN grade (Grade I: 87.5%; Grade II: 59.6%; Grade III: 50.0%; p = 0.0376). Logistic regression analysis demonstrated that PANOMEN-3 grade ≥ 2 was significantly associated with failure to achieve remission (OR 4.54, 95% CI 1.12–18.48, p = 0.034). ROC analysis demonstrated moderate discriminative performance (AUC 0.69). Ki-67 showed a moderate correlation with PANOMEN grade but was not significantly associated with remission.
conclusionsThe PANOMEN-3 classification is associated with early postoperative remission and may provide clinically relevant information for risk stratification in pituitary adenomas. These findings complement previous studies focused on long-term outcomes and suggest that PANOMEN-3 may also have value in the early postoperative setting. Further studies are needed to determine whether early remission predicts long-term disease control.
Indexed as
Identifiers
42008070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.